Advertisement

Connective Tissue Growth Factor and Renal Fibrosis

  • Qing Yin
  • Hong LiuEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1165)

Abstract

CCN2, also known as connective tissue growth factor (CTGF), is one of important members of the CCN family. Generally, CTGF expresses at low levels in normal adult kidney, while increases significantly in various kidney diseases, playing an important role in the development of glomerular and tubulointerstitial fibrosis in progressive kidney diseases. CTGF is involved in cell proliferation, migration, and differentiation and can promote the progression of fibrosis directly or act as a downstream factor of transforming growth factor β (TGF-β). CTGF also regulates the expression and activity of TGF-β and bone morphogenetic protein (BMP), thereby playing an important role in the process of kidney repair. In patients with chronic kidney disease, elevated plasma CTGF is an independent risk factor for progression to end-stage renal disease and is closely related to glomerular filtration rate. Therefore, CTGF may be a potential biological marker of kidney fibrosis, but more clinical studies are needed to confirm this view. This section briefly describes the role and molecular mechanisms of CTGF in renal fibrosis and also discusses the potential value of targeting CCN2 for the treatment of renal fibrosis.

Keywords

Connective tissue growth factor Renal fibrosis TGF-β 

Notes

Acknowledgements

This study was supported by grants from the National Key Research and Development Program of China (2018YFC1314004).

References

  1. Abreu JG, Ketpura NI, Reversade B, De Robertis EM (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 4:599–604CrossRefGoogle Scholar
  2. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T et al (2010) Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5:1420–1428CrossRefGoogle Scholar
  3. Behnes M, Brueckmann M, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M et al (2014) Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure. Clin Res Cardiol 103:107–116CrossRefGoogle Scholar
  4. Bradham DM (1991) Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. The Journal of Cell Biology 114:1285–1294CrossRefGoogle Scholar
  5. Chen CC, Lau LF (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41:771–783CrossRefGoogle Scholar
  6. Chen L, Liu BC, Zhang XL, Zhang JD, Liu H, Li MX (2006) Influence of connective tissue growth factor antisense oligonucleotide on angiotensin II-induced epithelial mesenchymal transition in HK2 cells. Acta Pharmacol Sin 27:1029–1036CrossRefGoogle Scholar
  7. Chung AC, Zhang H, Kong YZ, Tan JJ, Huang XR, Kopp JB et al (2010) Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 21:249–260CrossRefGoogle Scholar
  8. Crean JK, Finlay D, Murphy M, Moss C, Godson C, Martin F et al (2002) The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem 277:44187–44194CrossRefGoogle Scholar
  9. Dai HY, Zheng M, Lv LL, Tang RN, Ma KL, Liu D et al (2012) The roles of connective tissue growth factor and integrin-linked kinase in high glucose-induced phenotypic alterations of podocytes. J Cell Biochem 113:293–301CrossRefGoogle Scholar
  10. Dai H, Zhang Y, Yuan L, Wu J, Ma L, Shi H (2016) CTGF mediates high-glucose induced epithelial-mesenchymal transition through activation of beta-catenin in podocytes. Ren Fail 38:1711–1716CrossRefGoogle Scholar
  11. Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R (2011) Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 16:289–301CrossRefGoogle Scholar
  12. Falke LL, Leeuwis JW, Lyons KM, Mummery CL, Nguyen TQ, Goldschmeding R (2017) CCN2 reduction mediates protective effects of BMP7 treatment in obstructive nephropathy. J Cell Commun Signal 11:39–48CrossRefGoogle Scholar
  13. Fragiadaki M, Hill N, Hewitt R, Bou-Gharios G, Cook T, Tam FW et al (2012) Hyperglycemia causes renal cell damage via CCN2-induced activation of the TrkA receptor: implications for diabetic nephropathy. Diabetes 61:2280–2288CrossRefGoogle Scholar
  14. Gao R, Brigstock DR (2004) Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem 279:8848–8855CrossRefGoogle Scholar
  15. Gao R, Brigstock DR (2006) A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells. Gut 55:856–862CrossRefGoogle Scholar
  16. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R (2007) Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21:3355–3368CrossRefGoogle Scholar
  17. Hall-Glenn F, Lyons KM (2011) Roles for CCN2 in normal physiological processes. Cell Mol Life Sci 68:3209–3217CrossRefGoogle Scholar
  18. Hilhorst M, Kok HM, Broekhuizen R, van Paassen P, van Breda Vriesman P, Goldschmeding R et al (2015) Connective tissue growth factor and the cicatrization of cellular crescents in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 30:1291–1299CrossRefGoogle Scholar
  19. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ et al (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853–861CrossRefGoogle Scholar
  20. Ito Y, Goldschmeding R, Kasuga H, Claessen N, Nakayama M, Yuzawa Y et al (2010) Expression patterns of connective tissue growth factor and of TGF-beta isoforms during glomerular injury recapitulate glomerulogenesis. Am J Physiol Renal Physiol 299:F545–F558CrossRefGoogle Scholar
  21. Kiwanuka E, Junker JP, Eriksson E (2017) Transforming growth factor beta1 regulates the expression of CCN2 in human keratinocytes via Smad-ERK signalling. Int Wound J 14:1006–1018CrossRefGoogle Scholar
  22. Klahr S, Morrissey J (2002) Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283:F861–F875CrossRefGoogle Scholar
  23. Leask A (2013) CCN2: a novel, specific and valid target for anti-fibrotic drug intervention. Expert Opin Ther Targets 17:1067–1071CrossRefGoogle Scholar
  24. Liu BC, Sun J, Chen Q, Ma KL, Ruan XZ, Phillips AO (2003) Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol 23:429–437CrossRefGoogle Scholar
  25. Liu BC, Chen L, Sun J, Huang HQ, Ma KL, Liu H et al (2006a) Connective tissue growth factor-mediated angiotensin II-induced hypertrophy of proximal tubular cells. Nephron Exp Nephrol 103:e16–e26CrossRefGoogle Scholar
  26. Liu BC, Huang HQ, Luo DD, Ma KL, Liu DG, Liu H (2006b) Connective tissue growth factor is associated with the early renal hypertrophy in uninephrectomized diabetic rats. Chin Med J 119:1010–1016CrossRefGoogle Scholar
  27. Liu Y, Li W, Liu H, Peng Y, Yang Q, Xiao L et al (2014) Inhibition effect of small interfering RNA of connective tissue growth factor on the expression of extracellular matrix molecules in cultured human renal proximal tubular cells. Ren Fail 36:278–284CrossRefGoogle Scholar
  28. Ma B, Kang Q, Qin L, Cui L, Pei C (2014) TGF-beta2 induces transdifferentiation and fibrosis in human lens epithelial cells via regulating gremlin and CTGF. Biochem Biophys Res Commun 447:689–695CrossRefGoogle Scholar
  29. Mendes FA, Coelho Aguiar JM, Kahn SA, Reis AH, Dubois LG, Romao LF et al (2015) Connective-tissue growth factor (CTGF/CCN2) induces astrogenesis and fibronectin expression of embryonic neural cells in vitro. PLoS ONE 10:e0133689CrossRefGoogle Scholar
  30. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K (2002) Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 7:1191–1204CrossRefGoogle Scholar
  31. Montford JR, Furgeson SB (2017) A new CTGF target in renal fibrosis. Kidney Int 92:784–786CrossRefGoogle Scholar
  32. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A et al (1999) Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis:a mouse fibrosis model. J Cell Physiol 181:153–159CrossRefGoogle Scholar
  33. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, Bovenschen N, Li Z, Xu L et al (2008) CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 19:2098–2107CrossRefGoogle Scholar
  34. Nonaka Takahashi S, Fujita T, Takahashi T, Wada Y, Fuke Y, Satomura A et al (2008) TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. J Nephrol 21:53–63PubMedGoogle Scholar
  35. Perbal A, Perbal B (2016) The CCN family of proteins: a 25th anniversary picture. J Cell Commun Signal 10:177–190CrossRefGoogle Scholar
  36. Rayego-Mateos S, Morgado-Pascual JL, Rodrigues-Diez RR, Rodrigues-Diez R, Falke LL, Mezzano S et al (2018) Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation. J Pathol 244:227–241CrossRefGoogle Scholar
  37. Ren Y, Du C, Yan L, Wei J, Wu H, Shi Y et al (2015) CTGF siRNA ameliorates tubular cell apoptosis and tubulointerstitial fibrosis in obstructed mouse kidneys in a Sirt1-independent manner. Drug Des Devel Ther 9:4155–4171CrossRefGoogle Scholar
  38. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM et al (2004) Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 27:1164–1170CrossRefGoogle Scholar
  39. Rooney B, O’Donovan H, Gaffney A, Browne M, Faherty N, Curran SP et al (2011) CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett 585:531–538CrossRefGoogle Scholar
  40. Ruperez M, Ruiz-Ortega M, Esteban V, Lorenzo O, Mezzano S, Plaza JJ et al (2003) Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 163:1937–1947CrossRefGoogle Scholar
  41. Sakai N, Nakamura M, Lipson KE (2017) Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. 7:5392Google Scholar
  42. Samarakoon R, Higgins PJ (2018) The cytoskeletal network regulates expression of the profibrotic genes PAI-1 and CTGF in vascular smooth muscle cells. Adv Pharmacol 81:79–94CrossRefGoogle Scholar
  43. Schecterson LC, Bothwell M (2010) Neurotrophin receptors: old friends with new partners. Dev Neurobiol 70:332–338PubMedGoogle Scholar
  44. Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP et al (2002) Identification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 99:4457–4465CrossRefGoogle Scholar
  45. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR 3rd, Carmichael DF (2001) The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 276:40659–40667CrossRefGoogle Scholar
  46. Smeets B, Steenbergen ML, Dijkman HB, Verrijp KN, te Loeke NA, Aten J et al (2006) Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice. Nephrol Dial Transplant 21:3087–3097CrossRefGoogle Scholar
  47. Suzuki D, Toyoda M, Umezono T, Uehara G, Zhang SY, Sakai T et al (2003) Glomerular expression of connective tissue growth factor mRNA in various renal diseases. Nephrology (Carlton) 8:92–97CrossRefGoogle Scholar
  48. Tachaudomdach C, Kantachuvesiri S, Changsirikulchai S, Wimolluck S, Pinpradap K, Kitiyakara C (2012) Connective tissue growth factor gene expression and decline in renal function in lupus nephritis. Exp Ther Med 3:713–718CrossRefGoogle Scholar
  49. Toda N, Mori K, Kasahara M, Ishii A, Koga K, Ohno S et al (2017) Crucial role of mesangial cell-derived connective tissue growth factor in a mouse model of anti-glomerular basement membrane glomerulonephritis. Sci Rep 7:42114CrossRefGoogle Scholar
  50. Tominaga T, Abe H, Ueda O, Goto C, Nakahara K, Murakami T et al (2011) Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J Biol Chem 286:20109–20116CrossRefGoogle Scholar
  51. Tu Z, Shi Y, Wang J, Bao J, Bu H (2007) Upregulation of connective tissue growth factor in a rat model of chronic allograft nephropathy. Nephrology (Carlton) 12:166–171CrossRefGoogle Scholar
  52. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS et al (2001) Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142:1760–1769CrossRefGoogle Scholar
  53. Wahab NA, Weston BS, Mason RM (2005) Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 16:340–351CrossRefGoogle Scholar
  54. Wang S, Hirschberg R (2003) BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 284:F1006–F1013CrossRefGoogle Scholar
  55. Wang X, McLennan SV, Twigg SM (2011) CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells. J Cell Commun Signal 5:193–200CrossRefGoogle Scholar
  56. Wang S, Li B, Li C, Cui W, Miao L (2015) Potential renoprotective agents through inhibiting CTGF/CCN2 in diabetic nephropathy. J Diabetes Res 2015:962383PubMedPubMedCentralGoogle Scholar
  57. Wong CKS, Falkenham A, Myers T, Legare JF (2018) Connective tissue growth factor expression after angiotensin II exposure is dependent on transforming growth factor-beta signaling via the canonical Smad-dependent pathway in hypertensive induced myocardial fibrosis. J Renin Angiotensin Aldosterone Syst 19:1470320318759358CrossRefGoogle Scholar
  58. Wu YL, Li HY, Zhao XP, Jiao JY, Tang DX, Yan LJ et al (2017) Mesenchymal stem cell-derived CCN2 promotes the proliferation, migration and invasion of human tongue squamous cell carcinoma cells. Cancer Sci 108:897–909CrossRefGoogle Scholar
  59. Xing X, Li Z, Yu Z, Cheng G, Li D, Li Z (2018) Effects of connective tissue growth factor (CTGF/CCN2) on condylar chondrocyte proliferation, migration, maturation, differentiation and signalling pathway. Biochem Biophys Res Commun 495:1447–1453CrossRefGoogle Scholar
  60. Yang M, Huang H, Li J, Li D, Wang H (2004) Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation. FASEB J 18:1920–1921CrossRefGoogle Scholar
  61. Yokoi H, Mukoyama M, Mori K, Kasahara M, Suganami T, Sawai K et al (2008) Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 73:446–455CrossRefGoogle Scholar
  62. Zhang Q, Shu FL, Jiang YF, Huang XE (2015) Influence of expression plasmid of connective tissue growth factor and tissue inhibitor of metalloproteinase-1 shRNA on hepatic precancerous fibrosis in rats. Asian Pac J Cancer Prev 16:7205–7210CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Institute of Nephrology, Zhong Da HospitalSoutheast University School of MedicineNanjingChina

Personalised recommendations